A First-in-human of Multiplle Doses of BB-1705 in Subjects With Locally Advanced/Metastatic Solid Tumors

Solid Tumor Clinical Trial

Official title:

A Phase I First-in-human, Open Label, Multicenter, Dose Escalation and Cohort Expansion Study to Investigate the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of BB-1705 in Patients With Locally Advanced/Metastatic Solid Tumors

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05217693
• Other study ID #: BB-1705-101
• Status: Recruiting
• Phase: Phase 1
• Start date: June 1, 2022
• Est. completion date: December 2025

Study information

• Verified date: December 2023
• Source: Bliss Biopharmaceutical (Hangzhou) Co., Ltd
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The study consists of two phases: dose-escalation (Phase I) and cohort expansion (Phase II).

Description:

Phase Ia is a dose escalation study to assess the safety and tolerability, and to determine the MTD or MAD and RP2D of BB-1705.

Phase Ib is a cohort expansion study to explore one or more RP2Ds to further assess safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity. Patients with locally advanced and unresectable or metastatic solid tumors who have progressed on prior lines of standard of care therapies will be enrolled in this study if eligible.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 288
• Est. completion date: December 2025
• Est. primary completion date: December 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 78 Years

Eligibility

Inclusion Criteria:

1. Willing and able to provide written informed consent form (ICF) for the trial.

2. Adult patients = 18 years at the time of signing ICF.

3. Patient must have a histologically or cytologically confirmed, locally advanced, unresectable, or metastatic solid tumors:

4. At least one measurable lesion as defined per RECIST Version 1.1.

5. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

6. Life expectancy =12 weeks.

7. Adequate organ function as indicated by the following laboratory values (had not received blood transfusion, EPO, G-CSF, or other medical support within the 14 days before the administration of BB-1705):

8. Women of childbearing potential and males with fertile female partner must be willing to use currently accepted reliable contraception method throughout the treatment period from ICF signed and for at least 6 months following the last dose of BB-1705. These measures include, but are not limited to, oral or implantable injections of hormonal contraceptives; intrauterine birth control ring or placement of IUS intrauterine device); or use of barrier methods such as condoms or septum and spermicide products. Postmenopausal women over 50 years of age must have been amenorrheic for at least 12 months to be considered of non-childbearing potential. Women of childbearing potential must have a negative pregnancy test = 7 days prior to the first dose of investigational product.

Exclusion Criteria:

1. Receiving cancer therapy (chemotherapy or other systemic anti-cancer therapies, immunotherapy, radiation therapy, or surgery) at the time of enrollment

2. Prior history of other malignancies.

3. Not recovered to baseline or = grade 1 adverse events from prior anti-cancer treatment.

4. Major surgery within 4 weeks and minor surgery within 2 weeks before the first dose or not fully recovered from surgery; or surgery planned during the time the patient is expected to participate in the study

5. Grade 2 or higher peripheral neuropathy.

6. Active pneumonitis/interstitial lung disease (ILD), a history of pneumonitis/ILD that required systemic steroids, received radiotherapy to lung field within 12 months before the first dose of study intervention, or current clinically relevant-lung disease

7. Symptomatic or untreated CNS metastases, or those requiring ongoing treatment for CNS metastases, including steroids (>10 mg of prednisone or 4 mg of dexamethasone) and antiepileptic agents.

8. Any other serious ongoing underlying medical conditions, including but not limited to, uncontrolled diabetes mellitus, active uncontrolled infection, vaccination within 4 weeks, active gastric ulcer, uncontrolled seizures, cerebrovascular incidents within 6 months of study entry, gastrointestinal bleeding within 3 months of study entry, severe signs and symptoms of coagulation and clotting disorders.

9. QTc interval =450 ms for male or =470 ms for female (Fridericia's formula) and patients with congenital long QT syndrome.

Related Conditions & MeSH terms

• Neoplasms
• Solid Tumor

Intervention

Drug:
• BB-1705
BB-1705 is an ADC consisting of an engineered humanized IgG1? monoclonal antibody conjugated to the cytotoxic agent eribulin via a cathepsin-cleavable valine-citrulline linker. BB-1705 has a molecular weight of approximately 152 kDa, including two molecules of eribulin via the linker.

Locations

Country	Name	City	State
China	Beijing Cancer Hospital	Beijing
China	Hunan Cancer Hospital	Changsha
China	First affiliated hospital of Gannan medical university	Ganzhou
China	Bliss Biopharmaceutical Co, Ltd	Hangzhou
China	Zhejiang University School of Medicine - The First Affiliated Hospital	Hanzhou
China	Linyi Cancer Hospital	Linyi
China	Jiangsu Province Hospital	Nanjing

Sponsors (1)

Lead Sponsor	Collaborator
Bliss Biopharmaceutical (Hangzhou) Co., Ltd

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of subjects with adverse events and serious adverse events	To evaluate the safety and tolerability of BB-1705	up to 2 years
Primary	Number of subjects with dose limiting toxicity (DLT)	Subjects are evaluated for all study drug related and treatment emergent toxicities based on the National Cancer Institute Common Toxicity Criteria for adverse events (NCI-CTCAE)	Cycle 1. Duration of each cycle is 21 days.
Primary	MTD	MTD is defined as the highest dose level at which no more than 1 out of 6 subjects experiences a DLT during the first cycle.	Cycle 1. Duration of each cycle is 21 days.
Secondary	Area under the serum concentration time curve from time 0 extrapolated to infinity (AUC0-inf)	To characterize the PK of BB-1705	Pre-dose and post-dose during Cycle 1 through Cycle 8. Duration of each cycle is 21 days.
Secondary	Maximum observed plasma concentration (Cmax)	To characterize the PK of BB-1705	Pre-dose and post-dose during Cycle 1 through Cycle 8. Duration of each cycle is 21 days.
Secondary	Incidence of anti-drug antibodies	To assess the immunogenicity of BB-1705	Cycle 1 Day 1, Cycle 1 Day 15, and Day 1 of Cycles 2, 4, 6, and 8. Duration of each cycle is 21 days.
Secondary	Objective response	To assess the preliminary anti-tumor activity of BB-1705	Every 6 weeks within 6 months and approximately every 9 weeks thereafter (up to 2 years)
Secondary	Progression Free Survival	To assess the preliminary anti-tumor activity of BB-1705	Every 6 weeks within 6 months and approximately every 9 weeks thereafter (up to 2 years)
Secondary	Duration of Response	To assess the preliminary anti-tumor activity of BB-1705	Every 6 weeks within 6 months and approximately every 9 weeks thereafter (up to 2 years)